K. Baranger, P. Giannoni, S. D. Girard, S. Girot, F. Gaven et al., Chronic treatments with a 5-HT 4 receptor agonist decrease amyloid pathology in the entorhinal cortex and learning and memory deficits in the 5xFAD mouse model of Alzheimer's disease, Neuropharmacology, vol.126, pp.128-141, 2017.

B. Benhamú, M. Martín-fontecha, H. Vázquez-villa, L. Pardo, and M. L. López-rodríguez, Serotonin 5-HT 6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease, J. Med. Chem, vol.57, pp.7160-7181, 2014.

A. Cavalli, M. L. Bolognesi, A. Minarini, M. Rosini, V. Tumiatti et al., Multi-target-directed ligands to combat neurodegenerative diseases, J. Med. Chem, vol.51, pp.347-372, 2008.

S. Cho and Y. Hu, Activation of 5-HT 4 receptors inhibits secretion of ?-amyloid peptides and increases neuronal survival, Exp. Neurol, vol.203, pp.274-278, 2007.

S. Claeysen, J. Bockaert, and P. Giannoni, Serotonin: a new hope in Alzheimer's disease?, ACS Chem. Neurosci, vol.6, pp.940-943, 2015.

S. Consolo, S. Arnaboldi, S. Giorgi, G. Russi, and H. Ladinsky, , 1994.

, -HT 4 receptor stimulation facilitates acetylcholine release in rat frontal cortex, Neuroreport, vol.5, pp.1230-1232

L. A. Dawson, H. Q. Nguyen, L. , and P. , In vivo effects of the 5-HT 6 antagonist SB-271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5-HT, glutamate and aspartate, Br. J. Pharmacol, vol.130, pp.23-26, 2000.

L. Dawson, H. Nguyen, and P. Li, The 5-HT(6) receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus, Neuropsychopharmacology, vol.25, pp.662-668, 2001.

N. M. De-bruin and C. G. Kruse, 5-HT 6 receptor antagonists: potential efficacy for the treatment of cognitive impairment in schizophrenia, Curr. Pharm. Des, vol.21, pp.3739-3759, 2015.

W. Deraredj-nadim, S. Chaumont-dubel, F. Madouri, L. Cobret, M. L. De-tauzia et al., Physical interaction between neurofibromin and serotonin 5-HT 6 receptor promotes receptor constitutive activity, Proc. Natl. Acad. Sci. U S A, vol.113, pp.12310-12315, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01407899

D. Dolles and M. Decker, Dual-acting compounds acting as receptor ligands and enzyme inhibitors,'' in Design of Hybrid Molecules for Drug Development, pp.137-165, 2017.

D. Dolles, M. Hoffmann, S. Gunesch, O. Marinelli, J. Möller et al., Structure-activity relationships and computational investigations into the development of potent and balanced dual-acting butyrylcholinesterase inhibitors and human cannabinoid receptor 2 ligands with pro-cognitive in vivo profiles, J. Med. Chem, vol.61, pp.1646-1663, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01837661

F. Duhr, P. Déléris, F. Raynaud, M. Séveno, S. Morisset-lopez et al., Cdk5 induces constitutive activation of 5-HT 6 receptors to promote neurite growth, Nat. Chem. Biol, vol.10, pp.590-597, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01178901

R. M. Eglen, D. W. Bonhaus, L. G. Johnson, E. Leung, and R. D. Clark, Pharmacological characterization of two novel and potent 5-HT 4 receptor agonists, RS67333 and RS67506, in vitro and in vivo, Br. J. Pharmacol, vol.115, pp.1387-1392, 1995.

J. M. Ellis and M. J. Fell, Current approaches to the treatment of Parkinson's disease, Bioorg. Med. Chem. Lett, vol.27, pp.4247-4255, 2017.

G. L. Ellman, K. D. Courtney, V. Andres, and R. M. Featherstone, A new and rapid colorimetric determination of acetylcholinesterase activity, Biochem. Pharmacol, vol.7, pp.90145-90154, 1961.

T. Freret, V. Bouet, A. Quiedeville, G. Nee, P. Dallemagne et al., Synergistic effect of acetylcholinesterase inhibition (donepezil) and 5-HT(4) receptor activation (RS67333) on object recognition in mice, Behav. Brain Res, vol.230, pp.304-308, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00821461

J. Ge and N. M. Barnes, 5-HT 4 receptor-mediated modulation of 5-HT release in the rat hippocampus in vivo, Br. J. Pharmacol, vol.117, pp.1475-1480, 1996.

P. Giannoni, F. Gaven, D. De-bundel, K. Baranger, E. Marchetti-gauthier et al., Early administration of RS 67333, a specific 5-HT 4 receptor agonist, prevents amyloidogenesis and behavioral deficits in the 5XFAD mouse model of Alzheimer's disease, Front. Aging Neurosci, vol.5, p.96, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01703910

G. Hashimoto, M. Sakurai, A. F. Teich, F. Saeed, F. Aziz et al., 5-HT 4 receptor stimulation leads to soluble A?PP? production through MMP-9 upregulation, J. Alzheimers Dis, vol.32, pp.437-445, 2012.

W. D. Hirst, T. O. Stean, D. C. Rogers, D. Sunter, P. Pugh et al., SB-399885 is a potent, selective 5-HT 6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models, Eur. J. Pharmacol, vol.553, pp.109-119, 2006.

N. Hooper, C. Fraser, and T. W. Stone, Effect of purines analogues on spontaneous alternation in mice, Psychopharmacology, vol.123, pp.250-257, 1996.

H. R. Irving, N. Tochon-danguy, K. A. Chinkwo, J. G. Li, C. Grabbe et al., Investigations into the binding affinities of different human 5-HT 4 receptor splice variants, Pharmacology, vol.85, pp.224-233, 2010.

D. Karila, T. Freret, V. Bouet, M. Boulouard, P. Dallemagne et al., Therapeutic potential of 5-HT 6 receptor agonists, J. Med. Chem, vol.58, pp.7901-7912, 2015.
URL : https://hal.archives-ouvertes.fr/hal-02043781

H. Kilbinger and D. Wolf, Effects of 5-HT 4 receptor stimulation on basal and electrically evoked release of acetylcholine from guinea-pig myenteric plexus, Naunyn Schmiedebergs Arch. Pharmacol, vol.345, pp.270-275, 1992.

J. Lalut, D. Karila, P. Dallemagne, and C. Rochais, Modulating 5-HT 4 and 5-HT 6 receptors in Alzheimer's disease treatment, Future Med. Chem, vol.9, pp.781-795, 2017.
URL : https://hal.archives-ouvertes.fr/hal-02043735

C. Lecoutey, D. Hédou, T. Freret, P. Giannoni, F. Gaven et al., Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment, Proc. Natl. Acad. Sci. U S A, vol.111, 2014.

V. Lelong, L. Lhonneur, F. Dauphin, and M. Boulouard, BIMU 1 and RS 67333, two 5-HT 4 receptor agonists, modulate spontaneous alternation deficits induced by scopolamine in the mouse, Naunyn Schmiedebergs Arch. Pharmacol, vol.367, pp.621-628, 2003.

F. Lezoualc'h, 5-HT 4 receptor and Alzheimer's disease: the amyloid connection, Exp. Neurol, vol.205, pp.325-329, 2007.

G. Lucas, V. Di-matteo, P. De-deurwaerdère, G. Porras, R. Martín-ruiz et al., Neurochemical and electrophysiological evidence that 5-HT 4 receptors exert a state-dependent facilitatory control in vivo on nigrostriatal, but not mesoaccumbal, dopaminergic function, Eur. J. Neurosci, vol.13, pp.889-898, 2001.

B. Marcos, F. J. Gil-bea, W. D. Hirst, M. Garcia-alloza, and M. J. Ramirez, Lack of localization of 5-HT 6 receptors on cholinergic neurons: implication of multiple neurotransmitter systems in 5-HT 6 receptor-mediated acetylcholine release, Eur. J. Neurosci, vol.24, pp.1299-1306, 2006.

C. Morpugo, A new design for the screening of CNS-active drugs in mice, Arzneimittelforschung, vol.11, pp.1727-1734, 1971.

R. Nirogi, A. R. Mohammed, A. K. Shinde, S. R. Gagginapally, D. M. Kancharla et al., Synthesis, structure-activity relationships, and preclinical evaluation of heteroaromatic amides and 1,3,4-oxadiazole derivatives as 5-HT 4 receptor partial agonists, J. Med. Chem, vol.61, pp.4993-5008, 2018.

F. Prati, A. De-simone, P. Bisignano, A. Armirotti, M. Summa et al., Multitarget drug discovery for Alzheimer's disease: triazinones as BACE-1 and GSK-3? inhibitors, Angew. Chem. Int. Ed Engl, vol.54, pp.1578-1582, 2015.

A. Quiedeville, M. Boulouard, K. Hamidouche, V. Da-silva-costa-aze, G. Nee et al., Chronic activation of 5-HT 4 receptors or blockade of 5-HT 6 receptors improve memory performances, Behav. Brain Res, vol.293, pp.10-17, 2015.
URL : https://hal.archives-ouvertes.fr/hal-02043824

C. Riemer, E. Borroni, B. Levet-trafit, J. R. Martin, S. Poli et al., Influence of the 5-HT 6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine, a potent and selective 5-HT 6 receptor antagonist, J. Med. Chem, vol.46, pp.1273-1276, 2003.

C. Rochais, C. Lecoutey, F. Gaven, P. Giannoni, K. Hamidouche et al., Multi target-directed ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT 4 R) agonist activities as potential agents against Alzheimer's disease: the design of donecopride, J. Med. Chem, vol.58, pp.3172-3187, 2015.

O. Russo, M. Cachard-chastel, M. Giner, J. Soulier, M. Berthouze et al., Design, synthesis, and biological evaluation of new 5-HT 4 receptor agonists: application as amyloid cascade modulators and potential therapeutic utility in Alzheimer's disease design, J. Med. Chem, vol.52, pp.2214-2225, 2009.

S. Shirazi-southall, D. E. Rodriguez, and G. G. Nomikos, Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat, Neuropsychopharmacology, vol.26, pp.583-594, 2002.

L. J. Steward, J. Ge, R. L. Stowe, D. C. Brown, R. K. Bruton et al., Ability of 5-HT 4 receptor ligands to modulate rat striatal dopamine release in vitro and in vivo, Br. J. Pharmacol, vol.117, pp.55-62, 1996.

D. Wilkinson, K. Windfeld, and E. Colding-jørgensen, Safety and efficacy of idalopirdine, a 5-HT 6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebocontrolled phase 2 trial, Lancet Neurol, vol.13, issue.14, p.70198, 2014.

S. Yahiaoui, K. Hamidouche, C. Ballandonne, A. Davis, J. S. De-oliveira-santos et al., Design, synthesis, and pharmacological evaluation of multitarget-directed ligands with both serotonergic subtype 4 receptor (5-HT 4 ) partial agonist and 5-HT 6 antagonist activities, as potential treatment of Alzheimer's disease, Eur. J. Med. Chem, vol.121, pp.283-293, 2016.
URL : https://hal.archives-ouvertes.fr/hal-02043759

M. Y. Zhang, Z. A. Hughes, E. H. Kerns, Q. Lin, and C. E. Beyer, Development of a liquid chromatography/tandem mass spectrometry method for the quantitation of acetylcholine and related neurotransmitters in brain microdialysis samples, J. Pharm. Biomed. Anal, vol.44, pp.586-593, 2007.